Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Ustekinumab is effective in biological refractory Crohn's disease patients-regardless of approval study selection criteria.

Saman S, Goetz M, Wendler J, Malek NP, Wehkamp J, Klag T.

Intest Res. 2019 May 31. doi: 10.5217/ir.2019.00012. [Epub ahead of print]

2.

Human Paneth cell α-defensin-5 treatment reverses dyslipidemia and improves glucoregulatory capacity in diet-induced obese mice.

Larsen IS, Fritzen AM, Carl CS, Agerholm M, Damgaard MTF, Holm JB, Marette A, Nordkild P, Kiens B, Kristiansen K, Wehkamp J, Jensen BAH.

Am J Physiol Endocrinol Metab. 2019 Jul 1;317(1):E42-E52. doi: 10.1152/ajpendo.00019.2019. Epub 2019 Mar 12.

PMID:
30860877
3.

Proteolytic Degradation of reduced Human Beta Defensin 1 generates a Novel Antibiotic Octapeptide.

Wendler J, Schroeder BO, Ehmann D, Koeninger L, Mailänder-Sánchez D, Lemberg C, Wanner S, Schaller M, Stange EF, Malek NP, Weidenmaier C, LeibundGut-Landmann S, Wehkamp J.

Sci Rep. 2019 Mar 6;9(1):3640. doi: 10.1038/s41598-019-40216-2.

4.

Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohn's Disease.

Klag T, Courth L, Ostaff MJ, Ott G, Stange EF, Malek NP, Seifarth W, Wehkamp J.

Inflamm Intest Dis. 2019 Feb;3(3):125-137. doi: 10.1159/000494026. Epub 2018 Nov 21.

5.

Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis.

Jaeger SU, Klag T, Hoeger K, Klumpp S, Escher M, Malek N, Stange E, Wehkamp J.

Inflamm Intest Dis. 2019 Feb;3(3):116-124. doi: 10.1159/000493979. Epub 2018 Nov 9.

6.

Paneth cell α-defensins HD-5 and HD-6 display differential degradation into active antimicrobial fragments.

Ehmann D, Wendler J, Koeninger L, Larsen IS, Klag T, Berger J, Marette A, Schaller M, Stange EF, Malek NP, Jensen BAH, Wehkamp J.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3746-3751. doi: 10.1073/pnas.1817376116. Epub 2019 Feb 11.

7.

Enterocutaneous fistula in severely active Crohn's disease: preoperative anti-TNF alpha treatment to limit bowel resection-report of a case.

Wilhelm P, Kirschniak A, Johannink J, Kaufmann S, Klag T, Wehkamp J, Falch C.

Int J Colorectal Dis. 2019 Feb;34(2):369-373. doi: 10.1007/s00384-018-3206-4. Epub 2018 Nov 29.

PMID:
30498853
8.

GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting.

Schoeler M, Klag T, Wendler J, Bernhard S, Adolph M, Kirschniak A, Goetz M, Malek N, Wehkamp J.

Therap Adv Gastroenterol. 2018 Aug 30;11:1756284818793343. doi: 10.1177/1756284818793343. eCollection 2018.

9.

Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach.

Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK.

Intest Res. 2018 Oct;16(4):522-528. doi: 10.5217/ir.2018.00073. Epub 2018 Oct 16.

10.

Histone deacetylase-mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured tissue.

Stebe-Frick S, Ostaff MJ, Stange EF, Malek NP, Wehkamp J.

Sci Rep. 2018 Aug 27;8(1):12886. doi: 10.1038/s41598-018-31125-x.

11.

Recent advances and emerging therapies in the non-surgical management of ulcerative colitis.

Wehkamp J, Stange EF.

F1000Res. 2018 Aug 7;7. pii: F1000 Faculty Rev-1207. doi: 10.12688/f1000research.15159.1. eCollection 2018. Review.

12.

β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor.

Klag T, Thomas M, Ehmann D, Courth L, Mailänder-Sanchez D, Weiss TS, Dayoub R, Abshagen K, Vollmar B, Thasler WE, Stange EF, Berg CP, Malek NP, Zanger UM, Wehkamp J.

Front Immunol. 2018 Jul 27;9:1735. doi: 10.3389/fimmu.2018.01735. eCollection 2018.

13.

Influence of NOD2 Variants on Trichuris suis ova Treatment Outcome in Crohn's Disease.

Jaeger SU, Schaeffeler E, Winter S, Tremmel R, Schölmerich J, Malek N, Stange EF, Schwab M, Wehkamp J.

Front Pharmacol. 2018 Jul 16;9:764. doi: 10.3389/fphar.2018.00764. eCollection 2018.

14.

[Crohn's Disease - New Therapies].

Klag T, Wehkamp J.

Dtsch Med Wochenschr. 2018 Jul;113(13):953-959. doi: 10.1055/a-0538-3671. Epub 2018 Jul 4. Review. German.

PMID:
29972839
15.

Coding variants in NOD-like receptors: An association study on risk and survival of colorectal cancer.

Huhn S, da Silva Filho MI, Sanmuganantham T, Pichulik T, Catalano C, Pardini B, Naccarati A, Polakova-Vymetálkova V, Jiraskova K, Vodickova L, Vodicka P, Löffler MW, Courth L, Wehkamp J, Din FVN, Timofeeva M, Farrington SM, Jansen L, Hemminki K, Chang-Claude J, Brenner H, Hoffmeister M, Dunlop MG, Weber ANR, Försti A.

PLoS One. 2018 Jun 21;13(6):e0199350. doi: 10.1371/journal.pone.0199350. eCollection 2018.

16.

Practical guidance for the management of iron deficiency in patients with inflammatory bowel disease.

Niepel D, Klag T, Malek NP, Wehkamp J.

Therap Adv Gastroenterol. 2018 Apr 26;11:1756284818769074. doi: 10.1177/1756284818769074. eCollection 2018. Review.

17.

Intestinal manipulation affects mucosal antimicrobial defense in a mouse model of postoperative ileus.

Stein K, Hieggelke L, Schneiker B, Lysson M, Stoffels B, Nuding S, Wehkamp J, Kikhney J, Moter A, Kalff JC, Wehner S.

PLoS One. 2018 Apr 13;13(4):e0195516. doi: 10.1371/journal.pone.0195516. eCollection 2018.

18.

Bacterial Periplasmic Oxidoreductases Control the Activity of Oxidized Human Antimicrobial β-Defensin 1.

Wendler J, Ehmann D, Courth L, Schroeder BO, Malek NP, Wehkamp J.

Infect Immun. 2018 Mar 22;86(4). pii: e00875-17. doi: 10.1128/IAI.00875-17. Print 2018 Apr.

19.

In the Wnt of Paneth Cells: Immune-Epithelial Crosstalk in Small Intestinal Crohn's Disease.

Armbruster NS, Stange EF, Wehkamp J.

Front Immunol. 2017 Sep 26;8:1204. doi: 10.3389/fimmu.2017.01204. eCollection 2017. Review.

20.

Endoscopic Balloon Dilation for Crohn's Disease-Associated Strictures.

Klag T, Wehkamp J, Goetz M.

Clin Endosc. 2017 Sep;50(5):429-436. doi: 10.5946/ce.2017.147. Epub 2017 Sep 29. Review.

21.

Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn's Disease.

Leinwand KL, Jones AA, Huang RH, Jedlicka P, Kao DJ, de Zoeten EF, Ghosh S, Moaddel R, Wehkamp J, Ostaff MJ, Bader J, Aherne CM, Collins CB.

J Crohns Colitis. 2017 Oct 27;11(11):1369-1380. doi: 10.1093/ecco-jcc/jjx096.

22.

High Demand for Psychotherapy in Patients with Inflammatory Bowel Disease.

Klag T, Mazurak N, Fantasia L, Schwille-Kiuntke J, Kirschniak A, Falch C, Goetz M, Malek NP, Enck P, Wehkamp J.

Inflamm Bowel Dis. 2017 Oct;23(10):1796-1802. doi: 10.1097/MIB.0000000000001216.

PMID:
28817460
23.

Endoscopic balloon dilatation of Crohn's-associated intestinal strictures: High patient satisfaction and long-term efficacy.

Rueda Guzmán A, Wehkamp J, Kirschniak A, Naumann A, Malek NP, Goetz M.

United European Gastroenterol J. 2016 Dec;4(6):794-799. doi: 10.1177/2050640616628515. Epub 2016 Jan 19.

24.

Intestinal Barrier Function and the Gut Microbiome Are Differentially Affected in Mice Fed a Western-Style Diet or Drinking Water Supplemented with Fructose.

Volynets V, Louis S, Pretz D, Lang L, Ostaff MJ, Wehkamp J, Bischoff SC.

J Nutr. 2017 May;147(5):770-780. doi: 10.3945/jn.116.242859. Epub 2017 Mar 29.

PMID:
28356436
25.

Ubiquitously expressed Human Beta Defensin 1 (hBD1) forms bacteria-entrapping nets in a redox dependent mode of action.

Raschig J, Mailänder-Sánchez D, Berscheid A, Berger J, Strömstedt AA, Courth LF, Malek NP, Brötz-Oesterhelt H, Wehkamp J.

PLoS Pathog. 2017 Mar 21;13(3):e1006261. doi: 10.1371/journal.ppat.1006261. eCollection 2017 Mar.

26.

Low-grade appendiceal mucinous neoplasm (LAMN) - 3-year endoscopic follow-up underlines benign course of LAMN type 1.

Klag T, Wehkamp J, Bösmüller H, Falch C, Johannink J, Malek NP, Kirschniak A, Goetz M.

Z Gastroenterol. 2017 Feb;55(2):149-152. doi: 10.1055/s-0042-121495. Epub 2017 Feb 13.

PMID:
28192848
27.

Recent advances in understanding and managing Crohn's disease.

Stange EF, Wehkamp J.

F1000Res. 2016 Dec 21;5:2896. doi: 10.12688/f1000research.9890.1. eCollection 2016. Review.

28.

Microbiome and chronic inflammatory bowel diseases.

Wehkamp J, Frick JS.

J Mol Med (Berl). 2017 Jan;95(1):21-28. doi: 10.1007/s00109-016-1495-z. Epub 2016 Dec 17. Review.

PMID:
27988792
29.

Acetylcholine-producing T cells in the intestine regulate antimicrobial peptide expression and microbial diversity.

Dhawan S, De Palma G, Willemze RA, Hilbers FW, Verseijden C, Luyer MD, Nuding S, Wehkamp J, Souwer Y, de Jong EC, Seppen J, van den Wijngaard RM, Wehner S, Verdu E, Bercik P, de Jonge WJ.

Am J Physiol Gastrointest Liver Physiol. 2016 Nov 1;311(5):G920-G933. doi: 10.1152/ajpgi.00114.2016. Epub 2016 Aug 11.

30.

A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease.

Schölmerich J, Fellermann K, Seibold FW, Rogler G, Langhorst J, Howaldt S, Novacek G, Petersen AM, Bachmann O, Matthes H, Hesselbarth N, Teich N, Wehkamp J, Klaus J, Ott C, Dilger K, Greinwald R, Mueller R; International TRUST-2 Study Group.

J Crohns Colitis. 2017 Apr 1;11(4):390-399. doi: 10.1093/ecco-jcc/jjw184.

31.

Intestinal barrier analysis by assessment of mucins, tight junctions, and α-defensins in healthy C57BL/6J and BALB/cJ mice.

Volynets V, Rings A, Bárdos G, Ostaff MJ, Wehkamp J, Bischoff SC.

Tissue Barriers. 2016 Jul 8;4(3):e1208468. doi: 10.1080/21688370.2016.1208468. eCollection 2016 Jul-Sep.

32.

In Reply.

Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF.

Dtsch Arztebl Int. 2016 Jul 1;113(26):462. doi: 10.3238/arztebl.2016.0462b. No abstract available.

33.

Crosstalk between microbiota, pathogens and the innate immune responses.

Günther C, Josenhans C, Wehkamp J.

Int J Med Microbiol. 2016 Aug;306(5):257-265. doi: 10.1016/j.ijmm.2016.03.003. Epub 2016 Mar 5. Review.

PMID:
26996809
34.

Inflammatory Bowel Disease.

Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF.

Dtsch Arztebl Int. 2016 Feb 5;113(5):72-82. doi: 10.3238/arztebl.2016.0072. Review.

35.

Medical Therapy of Perianal Crohn's Disease.

Klag T, Goetz M, Stange EF, Wehkamp J.

Viszeralmedizin. 2015 Aug;31(4):265-72. doi: 10.1159/000434664. Epub 2015 Jul 29. Review.

36.

Crohn's disease-derived monocytes fail to induce Paneth cell defensins.

Courth LF, Ostaff MJ, Mailänder-Sánchez D, Malek NP, Stange EF, Wehkamp J.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):14000-5. doi: 10.1073/pnas.1510084112. Epub 2015 Oct 28.

37.

Disulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide.

Hein KZ, Takahashi H, Tsumori T, Yasui Y, Nanjoh Y, Toga T, Wu Z, Grötzinger J, Jung S, Wehkamp J, Schroeder BO, Schroeder JM, Morita E.

Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13039-44. doi: 10.1073/pnas.1511197112. Epub 2015 Oct 5.

38.

Management of Crohn's disease - are guidelines transferred to clinical practice?

Klag T, Stange EF, Wehkamp J.

United European Gastroenterol J. 2015 Aug;3(4):371-80. doi: 10.1177/2050640615580228.

39.

Chronic Heavy Alcohol Use is Associated with Upregulated Paneth Cell Antimicrobials in Gastric Mucosa.

Ostaff MJ, Schäfer C, Courth L, Stebe SR, Ott G, Stange EF, Wehkamp J.

Clin Transl Gastroenterol. 2015 Jul 16;6:e103. doi: 10.1038/ctg.2015.26.

40.

Paneth cell α-defensin 6 (HD-6) is an antimicrobial peptide.

Schroeder BO, Ehmann D, Precht JC, Castillo PA, Küchler R, Berger J, Schaller M, Stange EF, Wehkamp J.

Mucosal Immunol. 2015 May;8(3):661-71. doi: 10.1038/mi.2014.100. Epub 2014 Nov 5.

41.

TCF-1-mediated Wnt signaling regulates Paneth cell innate immune defense effectors HD-5 and -6: implications for Crohn's disease.

Beisner J, Teltschik Z, Ostaff MJ, Tiemessen MM, Staal FJ, Wang G, Gersemann M, Perminow G, Vatn MH, Schwab M, Stange EF, Wehkamp J.

Am J Physiol Gastrointest Liver Physiol. 2014 Sep 1;307(5):G487-98. doi: 10.1152/ajpgi.00347.2013. Epub 2014 Jul 3.

42.

Intestinal barrier in inflammatory bowel disease.

Antoni L, Nuding S, Wehkamp J, Stange EF.

World J Gastroenterol. 2014 Feb 7;20(5):1165-79. doi: 10.3748/wjg.v20.i5.1165. Review.

43.

Defective antibacterial barrier in inflammatory bowel disease.

Klag T, Stange EF, Wehkamp J.

Dig Dis. 2013;31(3-4):310-6. doi: 10.1159/000354858. Epub 2013 Nov 14. Review.

PMID:
24246980
44.

Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance.

Nuding S, Gersemann M, Hosaka Y, Konietzny S, Schaefer C, Beisner J, Schroeder BO, Ostaff MJ, Saigenji K, Ott G, Schaller M, Stange EF, Wehkamp J.

PLoS One. 2013 Sep 11;8(9):e73867. doi: 10.1371/journal.pone.0073867. eCollection 2013.

45.

Antimicrobial peptides and gut microbiota in homeostasis and pathology.

Ostaff MJ, Stange EF, Wehkamp J.

EMBO Mol Med. 2013 Oct;5(10):1465-83. doi: 10.1002/emmm.201201773. Epub 2013 Aug 23. Review.

46.

Antimicrobial activity of high-mobility-group box 2: a new function to a well-known protein.

Küchler R, Schroeder BO, Jaeger SU, Stange EF, Wehkamp J.

Antimicrob Agents Chemother. 2013 Oct;57(10):4782-93. doi: 10.1128/AAC.00805-13. Epub 2013 Jul 22.

47.

Human colonic mucus is a reservoir for antimicrobial peptides.

Antoni L, Nuding S, Weller D, Gersemann M, Ott G, Wehkamp J, Stange EF.

J Crohns Colitis. 2013 Dec;7(12):e652-64. doi: 10.1016/j.crohns.2013.05.006. Epub 2013 Jun 17.

PMID:
23787054
48.

Cell-mediated reduction of human β-defensin 1: a major role for mucosal thioredoxin.

Jaeger SU, Schroeder BO, Meyer-Hoffert U, Courth L, Fehr SN, Gersemann M, Stange EF, Wehkamp J.

Mucosal Immunol. 2013 Nov;6(6):1179-90. doi: 10.1038/mi.2013.17. Epub 2013 Apr 10.

49.

Bacteria regulate intestinal epithelial cell differentiation factors both in vitro and in vivo.

Becker S, Oelschlaeger TA, Wullaert A, Vlantis K, Pasparakis M, Wehkamp J, Stange EF, Gersemann M.

PLoS One. 2013;8(2):e55620. doi: 10.1371/journal.pone.0055620. Epub 2013 Feb 13. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/13f3d7ee-a72c-4879-bedb-8e73b6b364ac. Vlantis, Katerina [added].

50.

Inflammatory bowel disease: an impaired barrier disease.

Jäger S, Stange EF, Wehkamp J.

Langenbecks Arch Surg. 2013 Jan;398(1):1-12. doi: 10.1007/s00423-012-1030-9. Epub 2012 Nov 18. Review.

PMID:
23160753

Supplemental Content

Loading ...
Support Center